Figure 1.
Identification of 2 subgroups with different immune infiltration patterns in a public dataset from newly diagnosed DLBCL patients. (A) Gene expression profiles (Affymetrix) of screening biopsies from 414 DLBCL patients downloaded from the Gene Expression Omnibus (GSE10846)7 were transformed by nonnegative matrix factorization, followed by unsupervised clustering, revealing 2 subgroups. The heat map (left panel) shows expression of top discriminating genes (n = 260) between the 2 subgroups that are independent of COO classification. The bands at the top show COO classification in comparison with new groups identified. PCA shows orthogonality between the 2 subgroups and COO classification (right panel). Principal component 1 segregates the 2 new subgroups identified, whereas principal component 2 shows segregation between ABC and GCB COO. Boxplots at the top and on the right show sample distribution by each of the 2 new subgroups identified and by COO for principal component 1 and principal component 2. (B) Results of GSEA pathway analysis presented using EnrichmentMap23 to display the most significant biological processes (adj. P < .001) in subgroup A (left panel) and subgroup B (right panel). (C) Deconvolution plot of inferred immune cell populations shown as log2-fold change in subgroup B relative to subgroup A. (D) Subgroup inclusion does not correlate with PFS in frontline DLBCL patients treated with R-CHOP from the GSE10846 dataset.

Identification of 2 subgroups with different immune infiltration patterns in a public dataset from newly diagnosed DLBCL patients. (A) Gene expression profiles (Affymetrix) of screening biopsies from 414 DLBCL patients downloaded from the Gene Expression Omnibus (GSE10846) were transformed by nonnegative matrix factorization, followed by unsupervised clustering, revealing 2 subgroups. The heat map (left panel) shows expression of top discriminating genes (n = 260) between the 2 subgroups that are independent of COO classification. The bands at the top show COO classification in comparison with new groups identified. PCA shows orthogonality between the 2 subgroups and COO classification (right panel). Principal component 1 segregates the 2 new subgroups identified, whereas principal component 2 shows segregation between ABC and GCB COO. Boxplots at the top and on the right show sample distribution by each of the 2 new subgroups identified and by COO for principal component 1 and principal component 2. (B) Results of GSEA pathway analysis presented using EnrichmentMap23  to display the most significant biological processes (adj. P < .001) in subgroup A (left panel) and subgroup B (right panel). (C) Deconvolution plot of inferred immune cell populations shown as log2-fold change in subgroup B relative to subgroup A. (D) Subgroup inclusion does not correlate with PFS in frontline DLBCL patients treated with R-CHOP from the GSE10846 dataset.

Close Modal

or Create an Account

Close Modal
Close Modal